Investments
113Portfolio Exits
28Partners & Customers
4About Amgen Ventures
Amgen Ventures, formed in 2004, is the corporate venture fund of Amgen. With an initial investment of $100 million, the fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients by transforming cutting-edge scientific discoveries into novel treatments for serious illness. As an important component of Amgen's overall outreach strategy, Amgen Ventures invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. The fund, which focuses primarily on areas of current therapeutic interest to Amgen, offers early-stage companies access to its extensive capabilities while providing insight into external research innovations that may pave the way for future collaborations. Investments are made on a case-by-case basis, but Amgen Ventures typically invests up to $2 to 3 million per company per round with $10m invested over the life of the company.
Want to inform investors similar to Amgen Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Amgen Ventures
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Amgen Ventures in 1 Expert Collection, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Research containing Amgen Ventures
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Amgen Ventures in 1 CB Insights research brief, most recently on Apr 6, 2021.
Latest Amgen Ventures News
Mar 10, 2023
QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million. The financing was led by EQT Life Sciences, investing from the LSP Dementia Fund, Sanofi Ventures, and Droia Ventures, with participation from the ALS Investment Fund and existing investors LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, and Sanford Biosciences. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
Amgen Ventures Investments
113 Investments
Amgen Ventures has made 113 investments. Their latest investment was in QurAlis as part of their Series B on March 3, 2023.
Amgen Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/9/2023 | Series B | QurAlis | $88M | No | ALS Investment Fund, Amgen Ventures, Dementia Discovery Fund, Dolby Family Ventures, DROIA Ventures, EQT Life Sciences, INKEF Capital, Mission Bay Capital, Mission BioCapital, Mitsui & Co. Global Investment, MP Healthcare Venture Management, Polaris Partners, Sanford Biosciences, Sanofi Ventures, and SV Health Investors | 10 |
11/15/2022 | Series C | Casma Therapeutics | $46M | Yes | 3 | |
10/17/2022 | Series C | Inversago Pharma | $69.06M | Yes | 7 | |
9/20/2022 | Series C | |||||
9/6/2022 | Seed VC - II |
Date | 3/9/2023 | 11/15/2022 | 10/17/2022 | 9/20/2022 | 9/6/2022 |
|---|---|---|---|---|---|
Round | Series B | Series C | Series C | Series C | Seed VC - II |
Company | QurAlis | Casma Therapeutics | Inversago Pharma | ||
Amount | $88M | $46M | $69.06M | ||
New? | No | Yes | Yes | ||
Co-Investors | ALS Investment Fund, Amgen Ventures, Dementia Discovery Fund, Dolby Family Ventures, DROIA Ventures, EQT Life Sciences, INKEF Capital, Mission Bay Capital, Mission BioCapital, Mitsui & Co. Global Investment, MP Healthcare Venture Management, Polaris Partners, Sanford Biosciences, Sanofi Ventures, and SV Health Investors | ||||
Sources | 10 | 3 | 7 |
Amgen Ventures Portfolio Exits
28 Portfolio Exits
Amgen Ventures has 28 portfolio exits. Their latest portfolio exit was Akili Interactive Labs on August 19, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/19/2022 | Reverse Merger | 4 | |||
12/20/2021 | Acq - Pending | 3 | |||
10/7/2021 | Reverse Merger | 8 | |||
Date | 8/19/2022 | 12/20/2021 | 10/7/2021 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | Acq - Pending | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 3 | 8 |
Amgen Ventures Acquisitions
1 Acquisition
Amgen Ventures acquired 1 company. Their latest acquisition was Saama Technologies on October 20, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
10/20/2021 | Debt | $79.25M | Acq - Fin | 14 |
Date | 10/20/2021 |
|---|---|
Investment Stage | Debt |
Companies | |
Valuation | |
Total Funding | $79.25M |
Note | Acq - Fin |
Sources | 14 |
Amgen Ventures Partners & Customers
4 Partners and customers
Amgen Ventures has 4 strategic partners and customers. Amgen Ventures recently partnered with University of California Berkeley on May 5, 2015.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/29/2015 | Partner | United States | 1 | ||
1/5/2015 | Partner | ||||
7/9/2013 | Licensor | ||||
5/9/2013 | Partner |
Date | 5/29/2015 | 1/5/2015 | 7/9/2013 | 5/9/2013 |
|---|---|---|---|---|
Type | Partner | Partner | Licensor | Partner |
Business Partner | ||||
Country | United States | |||
News Snippet | ||||
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.